Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: Antihypertensive effects and benefits beyond BP control
- 27 February 2010
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 86 (9-10) , 289-299
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and AlbuminuriaDiabetes Care, 2009
- Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End PointJACC, 2009
- MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptidesAmerican Journal of Physiology-Cell Physiology, 2008
- Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptorsJournal Of Hypertension, 2008
- Renin-angiotensin blockade and kidney diseaseThe Lancet, 2008
- Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Isolation and identification of proangiotensin-12, a possible component of the renin–angiotensin systemBiochemical and Biophysical Research Communications, 2006
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11Life Sciences, 1993